SEC Form 4 · accession 0001493152-15-001503
OncBioMune Pharmaceuticals, Inc · OBMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Constantin Dietrich
Officer — Chief Executive Officer · Director
Period of report
Apr 14, 2015
Accepted (ET)
Apr 17, 2015 · 5:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001362703
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 14, 2015 | P$0 | 17,774,136 | — | A | 18,074,136 | D | |
| Common StockF1 | Apr 14, 2015 | P$0 | 17,774,136 | — | A | 35,848,272 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The purchase price per share was $0.00000056.